ROTTERDAM, the Netherlands and GHENT, Belgium, December 1, 2011 /PRNewswire/ –
Funds will be Used to Progress Differentiated Therapeutic Antibody Programs into Clinical Development
arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal…
Popularity: 2% [?]

